Most Read Articles
Stephen Padilla, 16 Dec 2019
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Elaine Soliven, 17 Dec 2019
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.
4 days ago
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Adding metformin to TKI may be detrimental to nondiabetic patients with EGFR-positive NSCLC

19 Jan 2020

The concurrent use of metformin with the tyrosine kinase inhibitor (TKI) gefitinib does more harm than good, resulting in significantly worse outcomes and increasing the risk of diarrhoea in nondiabetic patients with nonsmall cell lung cancer (NSCLC) harbouring EFGR mutation, according to data from a phase II trial.

A total of 224 nondiabetic patients (median age, 59.6 years; 75.0 percent nonsmokers) with treatment-naïve stage IIIB–IV EGFR-mutated NSCLC were randomized to receive gefitinib plus either metformin (n=112) or placebo (n=112). The majority of patients had a stage IV disease, with adenocarcinoma being the predominant pathologic type.

The median follow-up duration was 19.15 months. Progression-free survival (PFS) rate at 1 year was similar in the metformin and placebo groups (41.2 percent vs 42.9 percent; p=0.6268), as was overall response rate (66 percent vs 66.7 percent, respectively).

However, the metformin-treated patients had slightly shorter PFS (median, 10.3 vs 11.4 months) and overall survival (median, 22.0 vs 27.5 months). In subgroup analysis, including patients with elevated levels of IL6, PFS did not significantly differ between the metformin and placebo groups.

In terms of safety, combining metformin with gefitinib resulted in a markedly higher incidence of diarrhoea compared with the control arm (78.38 percent vs 43.24 percent).

The findings do not support the concurrent use of metformin with first-line TKI therapy in nondiabetic patients with EGFR-mutated NSCLC, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 16 Dec 2019
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Elaine Soliven, 17 Dec 2019
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.
4 days ago
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.